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Abstract: This study investigated the effects of ponesimod, a selective S1P
1
 receptor modulator, 
on T lymphocyte subsets in 16 healthy subjects. Lymphocyte subset proportions and abso-
lute numbers were determined at baseline and on Day 10, after once-daily administration of 
ponesimod (10 mg, 20 mg, and 40 mg each consecutively for 3 days) or placebo (ratio 3:1). 
The overall change from baseline in lymphocyte count was −1,292±340×106 cells/L and 
275±486×106 cells/L in ponesimod- and placebo-treated subjects, respectively. This included 
a decrease in both T and B lymphocytes following ponesimod treatment. A decrease in naïve 
CD4+ T cells (CD45RA+CCR7+) from baseline was observed only after ponesimod treatment 
(−113±98×106 cells/L, placebo: 0±18×106 cells/L). The number of T-cytotoxic (CD3+CD8+) 
and T-helper (CD3+CD4+) cells was significantly altered following ponesimod treatment 
compared with placebo. Furthermore, ponesimod treatment resulted in marked decreases in 
CD4+ T-central memory (CD45RA−CCR7+) cells (−437±164×106 cells/L) and CD4+ T-effector 
memory (CD45RA−CCR7−) cells (−131±57×106 cells/L). In addition, ponesimod treatment led 
to a decrease of −228±90×106 cells/L of gut-homing T cells (CLA−integrin β7+). In contrast, 
when compared with placebo, CD8+ T-effector memory and natural killer (NK) cells were 
not significantly reduced following multiple-dose administration of ponesimod. In summary, 
ponesimod treatment led to a marked reduction in overall T and B cells. Further investigations 
revealed that the number of CD4+ cells was dramatically reduced, whereas CD8+ and NK cells 
were less affected, allowing the body to preserve critical viral-clearing functions.
Keywords: ponesimod, multiple dose, S1P
1
 receptor, lymphocyte subsets, CD45RA/CCR7
Introduction
The adaptive immune system is responsible for maintaining immune competence, 
and it relies on the constant circulation of lymphocytes between lymphoid organs 
and other tissues in the body. In order to fulfill their function as surveyors of 
cognate antigen, mature lymphocytes leave the thymus and bone marrow to enter the 
circulation and lymphatic system and reach secondary lymphoid organs.1 Lysophos-
pholipid sphingosine-1-phosphate (S1P), via the S1P
1
 receptor, has been shown to play 
a central role in the transit or egress of T lymphocytes out of the thymus as well as 
their movement between blood, lymphatics, and non-lymphoid tissues.2–5 S1P
1
 receptor 
modulators bind to the receptor resulting in its internalization, degradation, and down-
regulation (ie, functional antagonism). In this way, lymphocytes cannot respond to the 
S1P signal in the blood and remain in the secondary lymphoid system and the thymus.6 
This mechanism was foreseen as a possible therapeutic strategy in order to divert lym-
phocytes from sites of inflammation. Lymphocytes return to the blood and lymphatic 
correspondence: Pierre-eric Juif
Department of clinical Pharmacology, 
actelion Pharmaceuticals ltd, 
gewerbestrasse 16, ch-4123 
allschwil, switzerland
Tel +41 61 565 8890
Fax +41 61 565 6200
email pierre-eric.juif@actelion.com 
Journal name: Drug Design, Development and Therapy
Article Designation: Original Research
Year: 2017
Volume: 11
Running head verso: Jurcevic et al
Running head recto: Ponesimod-triggered changes in lymphocyte subsets
DOI: http://dx.doi.org/10.2147/DDDT.S120399
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
73
.1
26
.1
88
 o
n 
27
-J
ul
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2017:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
124
Jurcevic et al
circulation from their sites of sequestration following 
withdrawal of an S1P
1
 receptor modulator.3 On this basis, 
selective (eg, ponesimod) and non-selective (eg, fingolimod 
[Gilenya®]) S1P
1
 receptor modulators have been developed 
for the treatment of autoimmune diseases such as multiple 
sclerosis (MS).7–9 These immunomodulators affect different 
subpopulations of lymphocytes.10,11 In this study, we have 
extended the investigation of the lymphocyte subsets to 
include T-central memory (TCM) and T-effector memory 
(TEM) subpopulations. These subpopulations are defined 
by the expression of surface markers CD45RA and CCR7.12 
As TCM and TEM cells and their CD4+ (helper T cells) 
and CD8+ (cytotoxic T cells) subtypes are thought to play 
distinct roles in immunopathology and protection against 
viral infections, the effects of multiple-dose treatment 
with ponesimod on these T cell subsets could elucidate 
the therapeutic mechanisms associated with selective S1P
1
 
receptor modulation.
Methods
subjects and study design
The details (ie, inclusion and exclusion criteria, study design, 
and demographics) of this double-blind, placebo-controlled, 
parallel-group, randomized, up-titration study have been 
previously described.13 Briefly, 16 subjects received either 
ponesimod or placebo (ratio 3:1) with an up-titration 
scheme from 10 mg to 100 mg. The up-titration scheme was 
used since in previous studies this was found to diminish 
the effects on heart rate observed with administration 
of ponesimod.14,15
Subjects were administered the following ascending doses 
of ponesimod/placebo for 3 days each: 10 mg, 20 mg, 40 mg, 
60 mg, 80 mg, and 100 mg. The study drug was administered 
once daily (o.d.) in the morning (fasted conditions) for a total 
of 18 days. Written informed consent was obtained from all 
individual participants included in the study.
Flow cytometry analysis
On Day 1 pre-dose (baseline) and on Day 10 (prior to 
the first administration of 60 mg ponesimod), 1.5 mL of 
blood was collected into ethylene diamine tetraacetic acid 
(EDTA) tubes and analyzed within 24 hours for lympho-
cyte subsets using four-color flow cytometry. The num-
ber of circulating T lymphocytes (CD3+), helper T cells 
(CD3+CD4+), cytotoxic T cells (CD3+CD8+), TCM cells 
(CD45RA−CCR7+), TEM cells (CD45RA−CCR7−), effec-
tor T cells (CD45RA+CCR7−), natural killer (NK) cells 
(CD3−CD56+), natural killer T (NKT) cells (CD3+CD56+), 
regulatory T cells (CD25+FoxP3+), and B cells (CD19+) was 
determined using flow cytometry. Monoclonal antibodies 
for specific cell markers were conjugated to fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), allophycocya-
nin (APC), or peridinin chlorophyll protein (PerCP). More 
specifically, CD3–APC/CD4–PE/CD45RA–FITC/CCR7– 
phycoerythrin-cyanine dye (PECy7) antibodies were used 
to determine percent (%) of CD3+CD4+CD45RA±CCR7± 
cells, CD3–APC/CD8–PE/CD45RA–FITC/CCR7–
PECy7 to determine % of CD3+CD8+CD45RA±CCR7± 
cells, CD45–PE/CD3–APC/CD19–FITC to determine 
% of CD3+ and CD3−CD19+ cells, CD45–PE/CD3–APC/
CD56–AlexaFluor488 to determine % of CD3±CD56+ 
cells, CD4–FITC/CD25–PE/Foxp3–APC to determine % of 
CD4+CD25+Foxp3+ cells, and CD3–APC/CD4–PECy7/
CLA–FITC integrin to determine % of gut-homing T cells 
(CLA−integrin β7+) and skin-homing T cells (CLA+integrin 
β7−). Antibodies were purchased from BD Biosciences (San 
Jose, CA, USA), eBioscience (San Diego, CA, USA), and 
Insight Biotechnology (Middlesex, UK). Cells were analyzed 
using the Dako Cyan flow cytometer and Summit software. 
The instrument was calibrated using FluoroSpheres calibra-
tion beads (Dako, Glostrup, Denmark), and set-up tubes 
incorporating each individual antibody and unstained cells 
were run before each set of samples was analyzed in order 
to eliminate spectral overlap. The gating was determined 
using distinct forward and side scatter properties of the lym-
phocyte population. Furthermore, the gating was confirmed 
by staining with a lymphocyte-specific antibody CD3. The 
isotype controls for antibody staining were analyzed during 
the assay validation procedure.
statistical methods
Absolute count (expressed as number of cells/L) and 
percentage change from baseline in lymphocyte count 
are presented as mean (±standard deviation [SD]). Sta-
tistical analysis was performed using GraphPad Prism 6 
(GraphPad Software, La Jolla, CA, USA). Lymphocyte 
counts were compared by treatment group using one-way 
analysis of variance (ANOVA) and Bonferroni’s multiple 
comparison test. A P-value of ,0.05 was considered as 
statistically significant.
ethical approval
All procedures performed in studies involving human 
participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with 
the 1964 Declaration of Helsinki and its later amendments 
or comparable ethical standards. The study was approved by 
Wandsworth Research Ethics Committee.
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Results
effects on T and B lymphocytes
The overall mean lymphocyte count showed a marked 
decrease from baseline in ponesimod-treated subjects.13 
At baseline, the mean (±SD) lymphocyte count was 
1,908±387×106 cells/L and 1,825±287×106 cells/L in the 
ponesimod and placebo groups, respectively. On Day 10 
before administration of the first dose of 60 mg ponesimod, 
the mean total lymphocyte count was 617±112×106 cells/L in 
ponesimod-treated subjects (P,0.001 vs baseline), whereas 
an increase was observed in placebo-treated subjects to reach 
2,100±258×106 cells/L (P.0.05 vs baseline; P,0.001 pla-
cebo vs ponesimod on Day 10). The percentage change from 
baseline is depicted in Figure 1A.
A minimum mean lymphocyte count of 400×106 cells/L 
was reached on Day 10, 4 hours after the subjects received 
their first daily dose of 60 mg ponesimod.13 The mean count 
did not decrease further during the study with up-titration 
of the ponesimod dose to 80 mg and 100 mg daily. Impor-
tantly, the mean lymphocyte count was quickly reversible 
upon discontinuation of ponesimod; by Day 29 (10 days after 
discontinuation of treatment), the mean lymphocyte count 
was 1,600±228×106 cells/L compared to a mean baseline 
count of 1,908±387×106 cells/L.
Both T (CD3+) and B (CD3−CD19+) lymphocytes were 
affected by ponesimod treatment. The flow cytometry 
analysis results of the T and B cell subsets from a representa-
tive ponesimod-treated subject are shown in Figure S1.
In placebo-treated subjects, an increase in the mean count 
of T cells was observed (from 1,273±269×106 cells/L to 
1,507±139×106 cells/L), whereas a significant decrease (from 
1,399±311×106 cells/L to 334±86×106 cells/L; P,0.001; 
Figure 1B) was detected in ponesimod-treated subjects. 
Whereas the mean count of B cells (CD3−CD19+) slightly 
increased in the placebo group between Day 1 (186±49×106 
cells/L) and Day 10 (234±65×106 cells/L), a significant 
decrease was observed in ponesimod-treated subjects 
(from 215±63×106 cells/L to 46±18×106 cells/L; P,0.001; 
Figure 1E).
The analysis of the T cell subsets in ponesimod-treated 
subjects showed marked decreases in the mean count of 
helper (CD3+CD4+) and cytotoxic (CD3+CD8+) T cells. Helper 
and cytotoxic T cells increased from 687±110×106 cells/L 
to 848±46×106 cells/L and from 476±167×106 cells/L to 
554±135×106 cells/L, respectively, in the placebo group. 
In the ponesimod group, a significant decrease from 
801±222×106 cells/L to 115±47×106 cells/L (P,0.001 
Day 10 vs baseline; P,0.001 placebo vs ponesimod) and 
from 484±117×106 cells/L to 172±45×106 cells/L (P,0.001 
Day 10 vs baseline; P,0.001 placebo vs ponesimod) was 
observed for helper (CD3+CD4+) and cytotoxic (CD3+CD8+) 
T cells, respectively. Percentage change from baseline is 
represented in Figure 1C and D.
effects on cD4+ T cell subpopulations
The effects of ponesimod on the subpopulations of CD4+ 
T-helper cells were further analyzed by using CD45RA 
and CCR7 surface markers. The flow cytometry analysis 
of a representative ponesimod-treated subject is shown in 
Figure 2. The initial lymphocyte gate (graph not shown) was 
followed by gating on CD3+CD4+ T cells (Figure 2A and C, 
gate R6). The gated CD3+CD4+ T cells were further analyzed 
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Figure 1 effect of placebo and ponesimod on total T and B cells count.
Notes: reduction of (A) total lymphocytes, (B) cD3+ T cells, (C) cD4+ T-helper cells, (D) cD8+ T-cytotoxic cells, and (E) cD3−cD19+ B cells. histograms represent the 
mean and SD of the percentage change from baseline (ie, Day 1 pre-dose) after 9 days of treatment with either placebo (gray bars) or ponesimod (black bars). Significance 
code: ***P,0.001 student’s t-test placebo vs ponesimod.
Abbreviation: sD, standard deviation.
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for the expression of CD45RA (x axis) and CCR7 (y axis), 
as shown in Figure 2B and D. The relative decrease in the 
proportion of TEM cells (CD45RA−CCR7−) was prominent 
on flow cytometry graphs (Figure 2B and D), ie, from 18.9% 
at baseline to 9.6% on Day 10. In contrast, effector T cells 
(CD45RA+CCR7−) showed a relative proportional increase 
on Day 10 (7.2%) when compared to baseline (3.7%) 
(Figure 2B and D).
The relative changes in the proportion of T cell subsets 
were used to calculate absolute cell numbers based on the 
measurements of lymphocyte counts and appropriate flow 
cytometry gating. As shown in Figure 3A, the mean number 
of naïve CD4+ T cells (CD45RA+CCR7+) remained stable 
following placebo administration but fell sharply (from 
143±121×106 cells/L to 12±12×106 cells/L; P,0.05 vs base-
line; P,0.05 placebo vs ponesimod) after o.d. administration 
of ponesimod for 10 days. No significant change in the 
absolute number of effector CD4+ T cells was observed. This 
corresponds to the changes in relative proportion of these 
cells in flow cytometry graphs (Figure 2B and D); however, 
this might be related to the high variability observed at 
baseline in the ponesimod group. Mean percentage change 
from baseline revealed a slight difference between both 
groups (P.0.05; Figure 3B). In the placebo group, CD4+ 
TCM (CD45RA−CCR7+) and CD4+ TEM cells remained 
stable between Day 1 (TCM: 463±60×106 cells/L; TEM: 
118±57×106 cells/L) and Day 10 (TCM: 596±147×106 cells/L; 
TEM: 119±48×106 cells/L). Following treatment with pone-
simod, CD4+ TCM and TEM cells significantly fell from 
492±175×106 cells/L to 70±34×106 cells/L (P,0.001 Day 1 
vs Day 10 and P,0.001 placebo vs ponesimod) and from 
157±57×106 cells/L to 31±16×106 cells/L (P,0.001 Day 1 
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Figure 2 Flow cytometric analysis of cD3+cD4+ helper T cells expressing cD45ra and ccr7.
Notes: (A) The cD3+cD4+ T cells at baseline (Day 1) are gated (r6) and further analyzed for the expression of (B) cD45ra and ccr7 (r8 and r10). The same subject is 
analyzed after ponesimod treatment on Day 10. (C) The cD3+cD4+ T cells are gated (r6) and further analyzed for the expression of (D) cD45ra and ccr7. The relative 
decrease of T effector memory cells (percentage of cD45ra−/ccr7− cells counted in gate r6) is shown in the lower left quadrant (9.6% on Day 10 vs 18.9% at Day 1 
baseline). in contrast, effector T cells (percentage of cD45ra+ccr7− cells counted in gate r6), lower right quadrant, show a relative increase on Day 10 (7.2% vs 3.7% at 
baseline). The increased number of cells in dot plots is reflected in the change in color from red to yellow, followed by green and blue for the highest number of cells.
Abbreviations: APC, allophycocyanin; PE, phycoerythrin; FITC, fluorescein isothiocyanate.
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vs Day 10 and P,0.001 placebo vs ponesimod), respectively 
(Figure 3C and D).
effects on cD8+ T cell subpopulations
The cytotoxic CD8+ T cell subpopulations were also further 
analyzed using surface expression of CD45RA and CCR7 
markers. A similar baseline for the placebo (190±92×106 
cells/L) and ponesimod (188±99×106 cells/L) groups was 
observed for the mean number of circulating naïve CD8+ 
cells. A slight increase was observed in the placebo group on 
Day 10 (235±78×106 cells/L), whereas a significant decrease 
was observed (12±5×106 cells/L on Day 10; P,0.0001; 
Figure 4A) in the ponesimod group. Despite a small decrease 
in the number of CD8+ effector T cells in the placebo group 
(from 64±27×106 cells/L to 50±17×106 cells/L), a significant 
drop was observed in ponesimod-treated subjects (from 
113±69×106 cells/L to 54±24×106 cells/L; P,0.05; 
Figure 4B). Ponesimod led to a significant decrease in 
CD8+ TCM cells count (Day 1: 32±17×106 cells/L, Day 10: 
8±4×106 cells/L; P,0.01), whereas this count was not 
affected by placebo treatment (Day 1: 50±25×106 cells/L, 
Day 10: 63±29×106 cells/L; P,0.001 placebo vs ponesi-
mod). Interestingly, no significant differences were observed 
when analyzing the percentage change from baseline in 
TCM cells between the treatments (Figure 4C). Similarly, 
although a trend was observed, the change in the number 
of CD8+ TEM cells was not significantly different between 
placebo- (from 172±94×106 cells/L to 205±74×106 cells/L) 
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and (D) TeM (cD45ra−ccr7−) cD4+ T cells on Day 10 post-dose with placebo or ponesimod. Data are presented as mean with SD. Significance code: *P,0.05, ***P,0.001; 
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Abbreviations: TCM, T-central memory; TEM, T-effector memory; SD, standard deviation; NS, not significant.
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and ponesimod-treated subjects (from 151±68×106 cells/L 
to 98±43×106 cells/L; Figure 4D).
effects on nK cells
The absolute number of NK cells (CD3−CD56+) was higher 
at baseline (211±109×106 cells/L and 268±65×106 cells/L 
in the placebo and ponesimod groups, respectively) than 
after placebo (142±81×106 cells/L; P.0.05) or ponesimod 
(100±35×106 cells/L; P,0.05) dosing. Comparison of per-
centage change from baseline revealed a similar decrease 
in placebo- (−44%±28%) and ponesimod-treated subjects 
(−36%±53%; P.0.05 placebo vs ponesimod; Figure 5A).
effects on regulatory T cells, nKT cells, 
gut-homing T cells, and skin-homing 
T cells
The number of regulatory T cells (CD25+Foxp3+) increased 
from 15±9×106 cells/L to 23±20×106 cells/L following treat-
ment with placebo but decreased (from 12±6×106 cells/L 
to 5±3×106 cells/L; P.0.05 baseline vs Day 10) following 
o.d. administration of ponesimod for 10 days. A significant 
difference between placebo and ponesimod treatment on 
Day 10 was observed (P,0.001; Figure 5B), although a 
large variability was observed in both groups.
Although analysis of the absolute number of NKT cells 
(CD3+CD56+) revealed that neither placebo nor ponesimod 
affected NKT cells count (P.0.05, baseline vs Day 10 
for both), comparison of percentage change from baseline 
revealed a statistically significant difference between placebo 
and ponesimod treatment (P,0.001; Figure 5C).
Mean count of gut-homing T cells (CLA−integrin β7+) 
was significantly decreased after 10 days of ponesimod 
treatment (from 258±80×106 cells/L to 32±17×106 cells/L; 
P,0.001), whereas there was no placebo effect (from 
267±114×106 cells/L to 364±186×106 cells/L; P.0.05). On 
Day 10, the number of gut-homing T cells was significantly 
lower in ponesimod- when compared to placebo-treated 
subjects (P,0.001; Figure 5D). The number of skin-
homing T cells (CLA+integrin β7−) increased following 
placebo (from 26±22×106 cells/L to 36±39×106 cells/L) but 
markedly decreased after treatment with ponesimod (from 
33±15×106 cells/L to 7±3×106 cells/L; P,0.01). Using 
percentage change from baseline, the change from baseline 
was significantly different between placebo and ponesimod 
treatment (P,0.001; Figure 5E).
Discussion
In this study, the effects of multiple-dose administration of 
ponesimod, a selective S1P
1
 receptor modulator, on lym-
phocyte subsets were investigated. In a previous study, we 
showed that single-dose administration of ponesimod leads to 
a higher reduction of naïve T cells and CD4+ T cells compared 
to memory T cells and CD8+ T cells.10 The pharmacokinet-
ics and safety and tolerability of the up-titration regimen 
employed in this study have been published previously13 
and revealed that on Day 10, when blood was sampled to 
further decipher the effects on lymphocyte subpopulations, 
the concentration of ponesimod in plasma was virtually at 
steady state.
The homeostasis of the immune system and outcome of 
inflammatory reactions depend on the compartmentalization 
of lymphocyte subsets and their ability to differentiate into 
pro-inflammatory and regulatory cells. The action of S1P
1
 
receptor modulators impedes the homing of these cells to 
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Figure 5 effect of placebo and ponesimod on nK cells, regulatory T cells, nKT cells, gut-homing T cells, and skin-homing T cells.
Notes: Percentage change from baseline (Day 1 pre-dose) in (A) peripheral nK cells (cD3−cD56+), (B) regulatory T cells (cD25+Foxp3+), (C) nKT cells (cD3+cD56+), 
(D) gut-homing (cla−integrin β7+), and (E) skin-homing (cla+integrin β7−) T cells on Day 10 post-dose with placebo or ponesimod. Data are presented as mean with sD. 
Significance code: **P,0.01, ***P,0.001; t-test placebo vs ponesimod.
Abbreviations: NK, natural killer; NKT, natural killer T memory; SD, standard deviation; NS, not significant.
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sites of inflammation and alters the delicate balance between 
lymphocyte retention and egress.
In this study, retention of CD4+ cells was more prominent 
compared to CD8+ cells. This is in agreement with previ-
ous studies with single-dose administration of ponesimod10 
and fingolimod.16 This might be related to the recruitment 
and priming of CD8+ cells that may occur in non-lymphoid 
organs.17
In addition to their immunological properties (eg, homing 
capacity or effector function), memory T cells can be dif-
ferentiated using the expression of two markers: CD45RA 
and CCR7.12 It has been shown that the expression of these 
markers and the number of cells in each phenotype remain 
fairly stable in the same individual but phenotypic distribu-
tion varies considerably between individuals.18 This variation 
is most notable in the CD8+ lymphocyte subsets and could 
help to explain the large variation in the expression of these 
markers observed in the placebo group.
It is known that chemokine receptor CCR7 is necessary 
for lymph node homing leading to the retention of CCR7+ 
cells (TCM and naïve cells) in secondary lymphoid organs.17 
TEM cells that do not express CCR7 are thought to migrate 
directly into target tissues where they can act as effector 
immune cells. In addition, an increase in the S1P
1
 receptor 
expression could influence the conversion of naïve T cells 
into effector and effector memory cells (CD45RA−) by down-
regulation of CCR7.4 In addition, S1P
1
 receptor expression is 
high in naïve T cells and low in effector and memory cells.19 
Taken together, this fully supports the present data and is in 
agreement with previous studies with fingolimod16 in which 
naïve T cells and TCM cells are more affected by selective 
and non-selective S1P receptor modulators compared to 
TEM cells and effector T cells that both continue to reside 
outside secondary lymphoid tissues. Although ponesimod 
effects on T cell subpopulations reported in this study fol-
low these general principles, as illustrated by the selective 
sparing of the CD8+ TEM cells, it is important to note that 
ponesimod treatment results in a distinct, significant decrease 
in CD4+ TEM cells. This differential effect on CD4+ TEM 
challenges the assumption that CD4+ and CD8+ TEM cells 
share similar migration mechanisms. Indeed, a recent study 
on the distribution of the human T cell subpopulations has 
reported that CD4+ TEM cells are primarily resting and 
compartmentalized, whereas CD8+ TEM cells show increased 
circulation through tissues.20 Furthermore, the lack of CCR7 
expression did not result in the exclusion of T cells from 
lymphoid organs, as 20%–50% of the total T cells found in 
human lymph nodes were CCR7− TEM cells. Thus, CD4+ 
TEM cells despite being CCR7− may enter the lymph nodes 
and their exit could be prevented by ponesimod. Indeed, a 
recent study in a mouse model has confirmed that the entry of 
CD4+ TEM cells into lymph nodes is independent of CCR7 
expression.21 Therefore, ponesimod treatment could reduce 
the number of CD4+ TEM cells in the blood, as these cells 
appear to be able to enter lymph nodes despite the lack of 
CCR7 expression and may require S1P
1
 receptor signal to 
exit into the circulation.
Nevertheless, the mechanisms that could explain the lack 
of similar effects on CD4+ TEM cells by non-selective S1P 
receptor modulators such as fingolimod remain to be clarified. 
The differential effects between ponesimod and fingolimod 
are likely due to the binding of the latter to S1P
3–5
 receptors. 
As S1P
4
 is expressed on immune cells, it is feasible that 
fingolimod binding to S1P
4
 could modulate S1P
1
 signaling22 
or may act indirectly by affecting T cell interaction with 
dendritic cells.23
Calculation of absolute numbers of T regulatory cells 
(CD25+Foxp3+) demonstrated a moderate non-significant 
decrease in the number of these cells circulating during 
ponesimod treatment. A study in chronic plaque psoriasis 
patients revealed that the effect of ponesimod on CD4+ T reg-
ulatory cells is low relative to the effect on conventional CD4+ 
T cells.9 Interestingly, a recent clinical study showed that MS 
patients have a decreased number of T regulatory cells and 
that fingolimod did not significantly change T regulatory 
cells count in MS patients.24 NKT cells (CD3+CD56+) do 
not require S1P
1
 receptor expression for development in the 
thymus, but the receptor is necessary for these cells to emerge 
into peripheral tissues. Once established, S1P
1
 receptor 
expression does not appear to alter the distribution of these 
cells.25 This observation is supported by data in a mouse 
model in which fingolimod did not alter the distribution of 
NKT cells within peripheral tissues.26 The absolute number 
of NKT cells on Day 10 was similar in the active and placebo 
groups, suggesting that these cells are largely unaffected by 
ponesimod. This could in part be due to the low rate of entry 
of NKT cells into lymph nodes due to their low expression 
of CCR7 and CD62L.25 Although NKT cells are a variable 
population with low numbers in peripheral blood, rendering 
their analysis difficult, the data in this study support previ-
ous observations in animal studies that absolute numbers or 
tissue distribution of NKT cells are largely unaffected by 
administration of an S1P
1
 receptor modulator.26
The effects of ponesimod on T cell subsets show con-
siderable overlap with the effects of the non-selective S1P 
receptor modulator fingolimod. However, our data provide 
clear evidence that the effects of ponesimod on T cell subsets 
are complex with distinct effects on CD4+ and CD8+ T cells 
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that do not conform to the mode of action of fingolimod. 
Here, we report that in contrast to fingolimod,27 ponesimod 
treatment results in a significant reduction in CD4+ TEM 
cells. This effect could be important in MS and other auto-
immune diseases, as CD4+ TEM cells potentially contribute 
to immunopathology.28,29
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Figure S1 Flow cytometry graphs showing reduction in the percentages of T and B cells after multiple-dose administration of ponesimod (Day 10).
Notes: (A) Baseline dot plot of whole blood stained with anti-cD45-Pe, cD3-aPc, and cD19-FiTc. cD45+ lymphocytes were gated (r1) using a cD45-Pe/ssc plot. 
(B) cD19-FiTc/cD3-aPc plot was generated when gated on r1. The percentage (%) of cD19+ B cells is shown in lower right quadrant and % cD3+ T cells in the upper 
left quadrant. (C) Day 10 dot plot of whole blood similarly stained. Flow cytometry profile shown is from a representative ponesimod-treated subject. (D) cD19-FiTc/
cD3-aPc plot was generated when gated on r6.
Abbreviations: PE, phycoerythrin; APC, allophycocyanin; FITC, fluorescein isothiocyanate; SSC, side scatter; lin, linear; log, logarithmic.
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